Skip to main content

Drug Interactions between Krystexxa and Proben-C

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

probenecid pegloticase

Applies to: Proben-C (colchicine / probenecid) and Krystexxa (pegloticase)

Using pegloticase together with probenecid is not recommended. Treatment with pegloticase requires monitoring of uric acid levels in the blood to reduce the risk of side effects such as allergic and infusion reactions, and probenecid can interfere with the monitoring. You should stop taking probenecid before your doctor begin treatment with pegloticase, and avoid taking it until the infusion is complete. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Major

colchicine food

Applies to: Proben-C (colchicine / probenecid)

Drinking large amounts of grapefruit juice can increase your blood levels of colchicine to dangerous levels. You should avoid the consumption of grapefruit or grapefruit juice during treatment with colchicine. Let your doctor know if you experience abdominal pain, nausea, vomiting, diarrhea, fever, muscle pain, weakness, fatigue, and/or numbness or tingling in your hands and feet, as these may be early symptoms of colchicine toxicity.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Anti-gout agents

Therapeutic duplication

The recommended maximum number of medicines in the 'anti-gout agents' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'anti-gout agents' category:

  • Krystexxa (pegloticase)
  • Proben-C (colchicine/probenecid)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.